GLP-1 receptor agonists are a class of peptides that mimic a hormone the gut releases after eating. Over the past several years, researchers have studied these compounds extensively for their effects on blood sugar and body weight. As more people have used them to reduce weight before elective surgery, surgeons have started noticing that some patients experience unexpected complications after procedures like abdominoplasty, a surgery that removes excess abdominal skin and fat.
A retrospective comparative study published in a peer-reviewed aesthetic surgery journal set out to answer a specific question: does it matter how long before surgery a patient stops taking a GLP-1 receptor agonist, and if so, by how much? The findings were clear enough that the authors called for standardized guidelines across surgical practices that see patients on this class of peptide.
Study design and patient groups
The researchers reviewed records from 80 patients who each underwent a procedure called lipoabdominoplasty, which combines liposuction with traditional abdominoplasty. All patients were matched for age, body mass index, and the specific surgical technique used, so the main variable between groups was GLP-1 peptide use and when it was stopped.
Patients were divided into four groups of equal size. Group A continued the peptide right up to the day of surgery. Group B stopped two weeks before the procedure. Group C stopped four weeks beforehand. Group D served as the control and had never used a GLP-1 receptor agonist at all. Researchers then tracked complications over a 30-day window following surgery.
What the complication data showed
The differences between groups were substantial. Group A, the patients who used the peptide until surgery, had a 45 percent complication rate. The complications recorded included wound dehiscence, which is when a surgical wound partially reopens, localized infection, and seroma formation, a condition where fluid collects under the skin at the surgical site. These are all recognized risks of abdominoplasty in any population, but the rate here was notably higher than in patients without peptide exposure.
Group B, which stopped the peptide two weeks out, showed moderate improvement with a 30 percent complication rate. That is still three times higher than the control group rate. The meaningful drop came in Group C, where the four-week discontinuation window brought complications down to 10 percent, matching the control group almost exactly. The published abstract notes that no patients in any group required reoperation or hospital readmission, which suggests the complications were serious enough to be clinically significant but not catastrophic.
Gastrointestinal effects and drain duration
Beyond wound-related complications, the study also tracked gastrointestinal intolerance and the duration that surgical drains needed to stay in place. Drains are tubes left at the surgical site to remove excess fluid, and longer drain duration is generally associated with increased seroma risk and slower recovery.
Both gastrointestinal intolerance and prolonged drain duration were more common in the groups where the GLP-1 peptide was continued closer to surgery. This finding is consistent with what researchers already understand about how GLP-1 receptor agonists work. These peptides slow gastric emptying, meaning food and liquid move through the stomach more slowly than normal. That effect does not disappear the moment a dose is skipped. The literature suggests that residual activity can persist for some time after the last dose, particularly with longer-acting formulations.
Why GLP-1 activity might affect surgical healing
The mechanism connecting GLP-1 receptor agonist use to surgical complications is not fully established in the literature, but several plausible pathways have been discussed by researchers. The slowed gastric emptying effect raises concerns about aspiration risk during anesthesia, which is when stomach contents enter the airway. Surgical and anesthesia teams have increasingly flagged this as a concern in patients on this class of peptide.
There may also be nutritional factors at play. GLP-1 receptor agonists suppress appetite and can lead to reduced caloric and protein intake. Adequate protein intake is widely recognized as important for wound healing. If patients arrive at surgery in a nutritionally depleted state after extended use of an appetite-suppressing peptide, tissue repair processes could be compromised. The study authors specifically highlighted nutritional assessment as an important component of pre-surgical planning for patients in this category.
Inflammatory response modulation is another area of interest. GLP-1 receptors are expressed in tissues beyond the gut, including in immune cells, and early research suggests these peptides may influence inflammatory signaling. Whether that plays a role in wound healing after elective surgery remains an open question that the retrospective design of this study was not built to answer.
Implications for perioperative protocols
The study authors argue that their findings support a standardized four-week discontinuation window as a safety measure before aesthetic surgical procedures in patients using GLP-1 receptor agonists. They also emphasize the need for interdisciplinary coordination, meaning communication between the prescribing physician, the surgeon, and ideally a nutrition professional.
A retrospective cohort study has inherent limitations. It looks backward at existing records rather than prospectively assigning patients to conditions, and 80 patients across four groups is a relatively small sample. The authors acknowledge these constraints. Still, the pattern across the groups is consistent and the effect size between Group A and Group C is large enough that the signal is difficult to dismiss as noise. Larger prospective trials would be needed to confirm the findings and to investigate whether the four-week window applies equally across all GLP-1 peptide formulations and dosing schedules.
For the broader research community, this study adds to a growing body of evidence suggesting that the pharmacological effects of GLP-1 receptor agonists do not disappear quickly after the last dose, and that timing of discontinuation before surgery may be a clinically meaningful variable worth standardizing.
Context within GLP-1 peptide research
GLP-1 receptor agonists as a class have been studied for more than two decades, initially in the context of type 2 diabetes management. More recently, research has expanded to their effects on body weight in non-diabetic populations, cardiovascular outcomes, and now perioperative safety. This study sits at the intersection of bariatric pharmacology and surgical medicine, a relatively new research territory that is generating increasing interest as the use of these peptides becomes more widespread.
The peptide at the center of this study is a long-acting GLP-1 receptor agonist administered weekly. Its extended half-life is part of what makes the discontinuation timing question important. A peptide that clears the body within hours would present a different risk profile than one with residual activity measured in weeks. Understanding that pharmacokinetic reality is central to interpreting why the two-week window produced only partial improvement while the four-week window aligned outcomes with those of peptide-naive patients.
